Flot.bio x Philip Hemme

Flot.bio
  • 0.0 (0)
  • 生命科学
  • 一月一更

Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Nielsen @BII, Edwin Moses, Bahija Jallal @Immunocore, and more. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian, ideas.

  1. Marc de Garidel, Abivax 🇫🇷 | Ulcerative Colitis, Inflammation | E46

    20分钟前

    Marc de Garidel, Abivax 🇫🇷 | Ulcerative Colitis, Inflammation | E46

    When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes. Philip meets Abivax CEO Marc de Garidel in Vienna, Austria, to go behind the scenes of a remarkable biotech turnaround. Marc discusses the processes involved in executing the phase 3 trial that beat even Abivax’s own phase 2 data. He also talks about France’s biotech ecosystem and the importance of having the right team. ⭐️ ABOUT THE SPEAKER Marc de Garidel joined Abivax as CEO in 2023. Prior to this, he led two biotech companies through billion-dollar exits (CinCor Pharma and Corvidia Therapeutics). He also served as CEO of Ipsen from 2010 to 2016, and has worked at the likes of Amgen and Eli Lilly. 🔗 LINKS MENTIONED Abivax’s website - https://www.abivax.com/Phase 3 results - https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week$747.5 million public offering - https://ir.abivax.com/news-releases/news-release-details/abivax-announces-closing-7475-million-public-offeringMarc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) | E09 - https://flot.bio/episode/marc-de-garidel-abivax-exit/Chris Martin, Verona Pharma 🇬🇧 | Ohtuvayre, COPD, Execution | E34 - https://flot.bio/episode/chris-martin-verona-pharma-copd/Christophe Bourdon, LEO Pharma 🇩🇰 | Biopharma Turnaround | E31https://flot.bio/episode/christophe-bourdon-leo-pharma-biopharma/Nanobiotix episode - https://www.youtube.com/watch?v=3Krhyy6a-nw&pp=0gcJCQMKAYcqIYzvFabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43 - https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/ 📜 TRANSCRIPT Read the full transcript here: 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS 0:44: Abivax’s crazy Ph3 data and stock price jump4:06: Surging investor demand on NASDAQ and Euronext8:58: Future directions11:02: Executing a Phase 3 home run17:20: Marc de Garidel's leadership style21:58: Abivax: origins34:51: France's billion-dollar biotechs44:11: Quick-fire questions

    54 分钟
  2. Laurent Levy, Nanobiotix 🇫🇷 | Nanoparticles, Radiotherapy | E45

    11月10日

    Laurent Levy, Nanobiotix 🇫🇷 | Nanoparticles, Radiotherapy | E45

    As Philip travels to France, Nanobiotix CEO Laurent Lévy discusses how the company broke into Europe’s exclusive $1 billion biotech club, alongside the likes of Abivax and Medincell. They also chat about what it means to partner with giants like Johnson & Johnson, and how Laurent’s leadership style has evolved over his long tenure. ⭐️ ABOUT THE SPEAKERLaurent Lévy co-founded Nanobiotics in 2003 and has served as CEO ever since. Before this, he worked in a variety of roles with companies including Altran Technologies, Valbiotis and Sanofi.He has a doctorate in nanomaterials-focused physical chemistry from the Pierre and Marie Curie University in Paris. 🔗 LINKS MENTIONED Nanobiotix website -- https://nanobiotix.com/Nanobiotix's $71 million deal with Healthcare Royalty -- https://ir.nanobiotix.com/news-releases/news-release-details/nanobiotix-announces-strategic-royalty-monetization-agreementNanobiotix's first phase 1 data -- https://ir.nanobiotix.com/news-releases/news-release-details/nanobiotix-announces-first-data-phase-1-study-evaluating-jnj 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/laurent-levy-nanobiotix-nanoparticles-radiotherapy/ 💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro[00:02:11] Soaring stocks with clinical results[00:04:08] Nanobiotix's history[00:07:39] Nanoparticles and radiotherapy[00:13:42] Developing NBTXR3[00:25:02] Universal cancer radiotherapy enhancers[00:28:28] Few competitors[00:33:37] Biotech in France, Europe and the US[00:37:19] Laurent Lévy’s leadership style[00:42:16] Quick-fire questions

    50 分钟
  3. Gerrit Sitters, LUMICKS 🇳🇱 | CAR-T therapy, Single-Cell Analysis | E44 [Sponsored]

    10月29日

    Gerrit Sitters, LUMICKS 🇳🇱 | CAR-T therapy, Single-Cell Analysis | E44 [Sponsored]

    As Philip tours Amsterdam, he visits the biotech tools startup LUMICKS. Founded in 2014, the firm offers products analyzing the binding interactions between molecules and cells, with applications in drug development, CAR-T therapies, and manufacturing. Philip sits down with co-founder Gerrit Sitters to discuss the company’s trajectory, the cyclic biotech investment market, and lessons from spinning the firm out from Vrije Universiteit Amsterdam. ---Explore how LUMICKS' technology helps develop biologics and cell therapies with unique cell avidity data — http://bit.ly/lumicks--- ⭐️ ABOUT THE SPEAKER Gerrit co-founded LUMICKS in 2014 following a PhD at Vrije Universiteit Amsterdam, and co-invented the technology behind LUMICKS’ main products. Gerrit now serves as Head of Product, where he aims to deploy the company’s products to tackle challenges in the life sciences. 🔗 LINKS MENTIONED LUMICKS’ website - https://www.lumicks.com/NanoTemper: https://flot.bio/episode/philipp-baaske-nanotemper-boostrapping-biotech/DNA Script: https://flot.bio/episode/thomas-ybert-dna-script-dna-printing/Adaptimmune: https://flot.bio/episode/adrian-rawcliffe-adaptimmune/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/gerrit-sitters-lumicks-car-t-therapy/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro[00:02:09] The history of LUMICKS[00:08:33] Visualizing microscopic interactions[00:14:29] Improving drug development[00:20:33] AI and digital labs[00:29:53] Quality control and manufacturing applications[00:31:58] Single-cell analysis and CAR-T[00:46:13] LUMICKS’ future milestones[00:47:13] Cyclic biotech market[01:00:15] Gerrit Sitters’ career takeaways[01:18:01] Quick-fire questions

    1 小时 25 分钟
  4. Fabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43

    10月21日

    Fabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43

    We travel to the offices of Pharming Group in Leiden, the Netherlands, to chat with the newcomer CEO Fabrice Chouraqui. Fabrice discusses the fascinating history of Pharming, with its first commercial drug RUCONEST produced in the milk of transgenic rabbits. He also talks about the growth of Pharming from a protein therapy-focused biotech into a European multi-asset heavyweight, with a market cap of at least €800 million. ⭐️ ABOUT THE SPEAKER Fabrice Chouraqui has been the CEO of Pharming Group since March 2024. Prior to this, he was a CEO-Partner at the US biotech venture capital firm Flagship Pioneering as well as CEO of the Flagship portfolio company Cellarity. He also served at Novartis and Bristol-Myers-Squibb for 10 years each, with his career beginning in R&D at pharmaceutical companies that were predecessors to today’s Sanofi. 🔗 LINKS MENTIONED - Pharming Group’s website - https://www.pharming.com/- Pharming Group’s second quarter and first half 2025 financial results - [https://www.pharming.com/sites/default/files/imce/Presentations/Pharming 2Q25_1H 2025 presentation_31JUL2025_website.pdf](https://www.pharming.com/sites/default/files/imce/Presentations/Pharming%202Q25_1H%202025%20presentation_31JUL2025_website.pdf)- Stefano Portolano, Azafaros 🇳🇱 🇨🇭 | Rare Diseases, Small Molecules | E40 -https://flot.bio/episode/stefano-portolano-azafaros-rare-disease/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS - [00:00:00] Intro- [00:02:12] Kicking off at Pharming- [00:04:26] RUCONEST and transgenic rabbits- [00:06:57] Path to profitability- [00:13:43] Encouraging stock price trends- [00:17:39] The protein and small molecules portfolio- [00:28:13] Switching gear to commercialization - [00:33:40] European biotech success stories- [00:39:55] Lessons from Fabrice Chouraqui’s career- [00:47:29] Quick-fire questions

    55 分钟
  5. Daniela Marino, CUTISS 🇨🇭 | Tissue Engineering, Skin Grafts | E42 [Sponsored]

    10月13日

    Daniela Marino, CUTISS 🇨🇭 | Tissue Engineering, Skin Grafts | E42 [Sponsored]

    Hot on the heels of CUTISS’ $60M Series C round, we catch up once more with CEO and co-founder Daniela Marino. We chat about the company’s mission to develop an engineered tissue therapy to reduce the need for skin grafts in patients with severe burns. She also explains the decentralization of tissue manufacturing with automation and the need for perseverance as a founder and CEO. ---This episode is sponsored by CUTISS, the only TechBio company in the advanced clinical stage of developing skin tissue therapies. Learn how you can support CUTISS on its path to Series C success: https://bit.ly/flotbio-cutiss--- ⭐️ ABOUT THE SPEAKER In 2023, Daniela Marino was named as one of the 30 Rising Leaders in the healthcare industry, thanks to the impact of CUTISS, the company she co-founded as a spin-off from the University of Zurich. Here, she and her team have made waves for people suffering from severe skin injuries and defects through regenerative medicine, tissue engineering, and skin pigmentation. 🔗 LINKS MENTIONED - CUTISS’ website – https://cutiss.swiss/- CUTISS’ Series C round – https://cutiss.swiss/cutiss-closes-chf-56m-series-c-round-and-signs-agreement-with-leading-european-burn-center/- CUTISS’ Phase II trial data – https://cutiss.swiss/phase-2-clinical-trials-update-from-cutiss/- Daniela Marino, CUTISS 🇨🇭 | Skin Tissue Therapeutics, TechBio | E33 – https://flot.bio/episode/daniela-marino-cutiss-skin-tissue-therapeutics/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/daniela-marino-cutiss-tissue-engineering/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro- [00:02:31] Investors in CUTISS’ Series C round [00:06:45] Expanding a hospital collaboration [00:08:34] Decentralized manufacturing drive [00:11:50] Tissue therapeutics vs skin grafts [00:24:35] Reimbursement and health economics [00:38:39] CUTISS’ partnering and exit options [00:47:54] Automation and artificial intelligence [00:56:32] Europe can show its strength in biotech [00:58:52] Daniela Marino answers quick-fire questions

    1 小时 8 分钟
  6. Dragan Grabulovski, Araris 🇨🇭 | ADC Linkers, Replacing Chemotherapy | E41

    10月8日

    Dragan Grabulovski, Araris 🇨🇭 | ADC Linkers, Replacing Chemotherapy | E41

    Philip meets up with Dragan Grabulovski, CEO of the startup Araris, at Lake Zurich to chat about the company’s work with antibody-drug conjugates (ADCs).They talk about Araris’ huge $400M upfront buyout by Taiho Pharma of Japan, Dragan’s extensive history as a biotech entrepreneur, and Araris’ vision to replace chemotherapy with ADCs.⭐️ ABOUT THE SPEAKERDragan Grabulovski is a co-founder of the startup Araris and became CEO in 2023. He previously worked as a biotech consultant and startup coach in Switzerland. He co-founded the biotech company Covagen in 2007, which was acquired by Johnson & Johnson in 2014. Dragan has a Master’s degree and a PhD in Pharmaceutical Sciences from ETH Zurich.🔗 LINKS MENTIONED- Araris’ website: https://www.ararisbiotech.com/- Taiho Pharma acquires Araris: https://www.ararisbiotech.com/docs/250316_250317-araris-taiho-pr.pdf- Robin Carr, Myricx Bio 🇬🇧 | New ADC Payloads, London Biotech Startups | E38: https://flot.bio/episode/robin-carr-myricx-bio-adc/- Dominik Schumacher, Tubulis 🇩🇪 | Founder-led ADC Biotech ⭐️ | E19: https://flot.bio/episode/dominik-schumacher-tubulis/- ETH entrepreneurship and terms: https://ethz.ch/staffnet/en/news-and-events/internal-news/archive/2025/07/new-business-creation-regulations-and-equity-and-licensing-policy.html 📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/dragan-grabulovski-araris-adc/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:02:08] Araris’ acquisition by Taiho Pharma- [00:08:29] Covagen: Dragan Grabulovski’s first exit- [00:12:54] The origins of Araris and its ADC tech- [00:22:14] How to value a technology platform - [00:29:34] The burgeoning ADC market- [00:41:53] ADCs replacing chemotherapy- [00:46:15] The Swiss biotech ecosystem- [01:00:53] Quickfire questions

    1 小时 9 分钟
  7. Stefano Portolano, Azafaros 🇳🇱 🇨🇭 | Rare Diseases, Small Molecules | E40

    10月1日

    Stefano Portolano, Azafaros 🇳🇱 🇨🇭 | Rare Diseases, Small Molecules | E40

    On a trip to Basel, Switzerland, Philip catches up with Stefano Portolano, CEO of the European firm Azafaros. They chat about Azafaros’ massive $147M Series B round in May 2025, which is being used to develop a small molecule treatment for rare diseases known as lysosomal storage disorders.Stefano also explains how rare diseases went in and out of fashion with big pharma, the revival of small molecule drugs relative to gene therapies and biologics, and his extensive experience in big biotech firms.⭐️ ABOUT THE SPEAKERWith more than 20 years of experience in orphan diseases under his belt, Stefano Portolano joined Azafaros in 2021. He previously served as Vice President, Strategy & Commercial Operations at Celgene and Head of Europe at Ultragenyx Pharmaceuticals.Stefano first received his Doctor of Medicine from Università degli Studi di Napoli ‘Federico II,’ Italy and carried out research in autoimmunity as an adjunct assistant professor of Medicine at the University of California, San Francisco, USA.🔗 LINKS MENTIONED- Azafaros website - https://www.azafaros.com/- Azafaros Series B round - https://www.azafaros.com/news/azafaros-secures-132m-in-oversubscribed-series-b-financing-to-advance-phase-3-clinical-programs-of-innovative-therapies-in-lysosomal-storage-disorders/l211c14- Joris Pezzini, Alira Health | Hottest Biotech Insights - https://flot.bio/episode/joris-pezzini-alira-health-biotech-trend/- Marc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) - https://flot.bio/episode/marc-de-garidel-abivax-exit/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/stefano-portolano-azafaros-rare-disease/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:01:45] Azafaros’ origin and $147M B round- [00:04:39] Developing nizubaglustat- [00:11:17] Competition in Niemann-Pick disease type C- [00:18:44] The small molecule revival- [00:24:29] Keeping options open- [00:27:23] Europe’s growing role in biotech investments- [00:30:12] The rare disease fashion- [00:51:20] Getting personal with Stefano Portolano- [01:11:11] Quickfire

    1 小时 19 分钟
  8. Alex Zhavoronkov, Insilico Medicine | AI Drug Development, Longevity | E39

    9月24日

    Alex Zhavoronkov, Insilico Medicine | AI Drug Development, Longevity | E39

    We chat about longevity with Alex Zhavoronkov, CEO and founder of the artificial intelligence (AI) specialist Insilico Medicine. Born in Latvia, Alex founded Insilico in 2014, with the company raising a huge $110M Series E round this year. Alex gives us a tour of Insilico’s sprawling pipeline, a blunt rundown of the competitive landscape in AI drug development, and explains how Insilico is navigating the huge challenges faced by longevity-focused startups. ⭐️ ABOUT THE SPEAKER Alex founded Insilico in 2014 after serving in senior roles at ATI Technologies, NeuroGNeuroinformatics, and the Biogerontology Research Foundation. With an academic background in biomedicine and computer technology, he has published more than 200 peer-reviewed articles, and has bachelor’s degrees from Queen's University, Canada, a master’s degree from Johns Hopkins University, US, and a PhD from Moscow State University, Russia. 🔗 LINKS MENTIONED Insilico Medicine’s website: https://insilico.com/Insilico Medicine’s phase 2a results: https://insilico.com/blog/1112Insilico Medicine’s Series E round: https://www.prnewswire.com/news-releases/insilico-medicine-secures-110-million-series-e-financing-to-advance-ai-driven-drug-discovery-innovation-302401040.htmlThomas Clozel, Owkin | What does AI Biotech really mean | E10: https://flot.bio/episode/thomas-clozel-ai-biotech/ 📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/alex-zhavoronkov-insilico-medicine-ai-drug-development-longevity/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS Intro [00:00:00][00:01:43] Longevity: work, romances and bromances[00:07:56] Survival in the graveyard of longevity drugs[00:14:57] Insilico Medicine comes of age[00:23:12] Landmark efficacy in AI drug program[00:28:15] A sprawling pipeline for Insilico Medicine[00:36:34] Small molecules vs biologics[00:40:57] Competition and benchmarks[00:52:20] Alex Zhavoronkov on longevity myths

    58 分钟
查看全部 46 集

关于

Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Nielsen @BII, Edwin Moses, Bahija Jallal @Immunocore, and more. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian, ideas.

信息

  • 创作者
    Flot.bio
  • 活跃年份
    2023年 - 2025年
  • 单集
    46
  • 分级
    儿童适宜
  • 版权
    © Flot.bio
  • 节目网站
    Flot.bio x Philip Hemme

你可能还喜欢